Related Experiment Video
Updated: Aug 8, 2026
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
4-Methylcatechol attenuates NLRP3 inflammasome activation to limit inflammation
Danhui Qin1, Yue Fu2, Hongyi Kong1
1Department of Pathogenic Biology, Key Laboratory of Infection and Immunity of Shandong Province, and Key Laboratory for Experimental Teratology of the Chinese Ministry of Education, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
4-methylcatechol (4-MC), a quercetin metabolite, inhibits NLRP3 inflammasome activation without cytotoxicity. This compound shows therapeutic potential for inflammatory diseases by reducing inflammasome activity and improving in vivo models.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- NLRP3 inflammasome activation is crucial for host defense but also implicated in inflammatory diseases.
- Targeting NLRP3 offers therapeutic potential, yet effective, low-toxicity inhibitors are needed.
- Quercetin metabolite 4-methylcatechol (4-MC) was identified as a potential inhibitor.
Purpose of the Study:
- To investigate the inhibitory effects of 4-methylcatechol (4-MC) on NLRP3 inflammasome activation.
- To elucidate the mechanism of 4-MC's action on NLRP3 inflammasome.
- To evaluate the therapeutic potential of 4-MC in vivo models of inflammation.
Main Methods:
- Compound library screening to identify NLRP3 inhibitors.
- In vitro assays to assess 4-MC's effect on NLRP3 inflammasome and NF-κB activation.
- In vivo studies using alum-induced peritonitis and LPS-induced sepsis models.
Main Results:
- 4-MC inhibited NLRP3 inflammasome activation at low concentrations without cytotoxicity.
- 4-MC did not affect NLRP3 expression or NF-κB activation.
- Increased intracellular ROS attenuated 4-MC's inhibitory effect.
- 4-MC ameliorated symptoms in peritonitis and sepsis models.
Conclusions:
- 4-methylcatechol (4-MC) is a potent, low-toxicity inhibitor of NLRP3 inflammasome activation.
- 4-MC demonstrates therapeutic efficacy in preclinical models of inflammatory diseases.
- 4-MC represents a promising candidate for treating NLRP3-mediated inflammatory conditions.
